Close

Amedra re-launches Adrenaclick to treat anaphylaxis

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Amedra Pharmaceuticals has re-launched a single-dose epinephrine auto-injector Adrenaclick for people with increased risk of anaphylaxis in both 0.15mg and 0.30mg strengths.

Potentially life-threatening allergic reaction, Anaphylaxis onsets rapidly and may cause severe swelling, breathing problems, loss of blood pressure, and death.

Indicated for the treatment of allergic reactions, Adrenaclick will be made available in 0.15mg and 0.30mg doses as two-pack carton.

The emergency injection (shot) of epinephrine is used for allergic reactions caused due to stinging and biting insects (bugs), allergy injections, food, medicines, exercise, or unknown causes.

 

Latest stories

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back